Acknowledgements
This work was financed by national funds through FCT - Fundação para a
Ciência e Tecnologia, I.P., within the scope of the Cardiovascular R&D
Center (UIDB/00051/2020 and UIDP/00051/2020) and RISE (LA/P/0053/2020),
for funding Institute of Biomedicine (iBiMED) (UIDB/04501/2020,
POCI-01-0145-FEDER-007628), by an individual scholarship from T.L.
(SFRH/ 725BD/136904/2018). All authors have read the journal’s
authorship agreement and policy on disclosure of potential conflicts of
interest. This study was also supported by the project “New targets in
diastolic heart failure: from comorbidities to personalized
medicine–NETDIAMOND”, financed by the European Structural and
Investment Funds (ESIF), through the Programa Operacional Regional
Lisboa 2020 (POCI-01-0145-FEDER-016385), national funds by FCT
(SAICTPAC/0047/2015. Fábio Trindade is a recipient of a post-doctoral
research grant by UnIC (UIDP/00051/2020). LP and LM is supported by a
doctoral fellowship by FCT (BD/10080/2022, SFRH/BD/145216/2019). COST
CA21153-AtheroNET. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD042493.